Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • About
    • Management
    • Corporate Governance
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • About
    • Management
    • Corporate Governance
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
Subscribe to Phase 3
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • About
    • Management
    • Corporate Governance
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement

© 2024 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.